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We read with great interest the article by
Szabo and associates1 in which they re-
ported the use of state-of-the-art animal
instrumentation and molecular biologic
techniques to demonstrate that poly–ade-
nosine diphosphate–ribose polymerase
(PARP) inhibition protects against myocar-
dial and endothelial reperfusion injury after
crystalloid cardioplegic arrest. In the dis-
cussion, they attributed this primarily to
energy-saving effects, because activation
and (more importantly) activity of the en-
zyme PARP require energy.1 However,
they did not address the physiologic func-
tions of PARP in repairing DNA breaks,
especially after DNA cleavage by caspases
as part of the apoptotic cascade, a geneti-
cally programmed process for the death
and subsequent removal of injured cells.2
Recent studies have shown that cardiople-
gic arrest induces the apoptosis signal cas-
cade in cardiac myocytes and endothelial
cells,3,4 so inhibition of the repair enzyme
PARP—even though energy sparing—may
result in higher numbers of cardiac myo-
cytes completing apoptosis, thus abolishing
any potential positive short-term effects at-
tributable to PARP inhibition.
Considering that the benefit of energy
sparing by PARP inhibition is necrosis
avoidance,5 the therapeutic concept of
PARP inhibition can only be effective if
the unprotected ischemia/reperfusion in-
jury leads to necrosis, such as in myocar-
dial infarction or stroke. If, however,
PARP activation does not lead to cellular
oxidized nicotinamide adenine dinucle-
otide (NAD) depletion by more than
75%,5 as has recently been demonstrated in
transient global cerebral ischemia, PARP
inhibition decreases the number of surviv-
ing cells.6 These data suggest that in the
absence of NAD depletion as induced by
mild ischemia-reperfusion injury (pro-
tected ischemia such as cardioplegic arrest)
PARP activation would be protective.
Therefore, the therapeutic use of PARP
inhibitors should be critically proved with
he Journal of Thoracic and Cardiovascularrespect to the degree of injury. Finally, it
must be questioned whether inhibition or
scavenging of upstream effectors of apo-
ptosis, such as reactive oxygen species,
would be more effective through reduction
of endogenous PARP activation parallel to
the inhibition of DNA damage and subse-
quent apoptosis. A study comparing inhi-
bition of upstream activators of ischemia-
reperfusion injury (reactive oxygen species
scavengers) versus PARP inhibition ap-
pears appropriate. Further issues that need
to be addressed before therapeutic PARP
inhibition are the various other physiologic
functions of activated PARP, including
transcriptional regulation, stimulation of
nuclear proteasomal function, and its anti-
aging effect.2 Certainly, these aspects are
beyond the scope of the study of Szabo and
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Reply to the Editor:
In response to the comments of Bloch and
Mehlhorn on the effects of poly–adenosine
diphosphate–ribose polymerase (PARP) in-
hibition after cardioplegic arrest and reper-
fusion, we agree that the PARP enzyme
family has a complex regulatory role under
several physiologic and pathologic condi-
tions. After a decade of intensive research,
we reported on the role of PARP in gener-
al1 and focusing on ischemia-reperfusion
injury.2,3 To date, the role of PARP in
physiologic DNA repair, apoptosis, and ne-
crosis can be summarized as follows: de-
pending on the severity of DNA damage,
genotoxic stimuli can trigger three different
pathways. In the case of mild DNA dam-
age, PARP facilitates DNA repair and thus
survival. However, the exact physiologic
role of PARP still remains to be clarified;
many authors have suggested that PARP is
an abundant enzyme with limited role un-
der physiologic conditions. More severe
DNA damage induces apoptotic cell death,
during which caspases, the main executor
enzymes of apoptotic process, inactivate
PARP, cleaving it into two fragments (p89
and p24) and thus PARP cleavage by
caspases is a marker of apoptotic cell
death. This pathway allows cells with ir-
reparable DNA damage to become elimi-
nated in a safe way. Much of the cell death
related literature focuses on PARP cleav-
age (as opposed to PARP activation). The
most severe DNA damage may cause ex-
cessive PARP activation, depleting oxi-
dized nicotinamide adenine dinucleotide
(NAD) and adenosine triphosphate stores.
NAD/ATP depletion blocks apoptosis
and results in necrosis. This pathway,
which we proposed in the article under
discussion, has no relationship to the PARP
cleavage pathway. As mentioned previ-
ously, the cleaved form of PARP is cata-
lytically inactive; PARP cleavage has been
considered as an endogenous mechanism
that serves to prevent PARP-dependent
metabolic suppression and necrosis.
Considering the previously mentioned
mechanisms, the cited study of Fischer and
colleagues4 is not contrary to but support-
ive of our results. They found caspase ac-
tivation but no apoptotic cell death and no
PARP cleavage in a similar model of car-
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On the basis of these findings, Bloch and
Mehlhorn criticized our study, suggesting
that pharmacologic PARP inhibition may
be detrimental by inhibiting physiologic
DNA repair and promoting apoptosis.
We do believe that the fact they did not
find apoptotic cell death and PARP cleav-
age (inactivated PARP) after cardioplegic
arrest indicates that the primary form of
cell damage is the necrotic (or prenecrotic)
pathway, with concomitant PARP activa-
tion instead of PARP cleavage. It is also
evident that cardioplegic arrest leads to
adenosine triphosphate depletion, and
therefore it is not surprising that no or
negligible apoptosis occurs during reperfu-
sion, because apoptosis is an adenosine
triphosphate–dependent process. The loss
of the ability of the cells to undergo apo-
ptosis results in missing PARP cleavage
and turns the cells toward PARP activation
and metabolic suppression. Indeed, there is
immunohistochemical evidence of PARP
activation in different models of cardiople-
gic arrest and reperfusion.2,5 It is also im-
portant to note that cellular PARP activa-
tion does not always need to culminate in
full-fledged cellular necrosis (complete
breakdown of cell membrane integrity and
release of cellular content into the extracel-
lular space); a partial, and reversible sup-
pression of cellular energetic pools can be
associated with reversible cell dysfunction.
These phenomena are sometimes termed
prenecrosis or cytopathic hypoxia and are
reversible by PARP inhibition.6,7
The questions raised about additional
functions of PARP, its potential toxicity,
and its role in aging were far beyond the
scope of our study; however, we refer to a
previous review article in which they were
discussed and considered in detail.1 We
note, nevertheless, that in addition to par-
ticipating in the NAD depletion/prenecro-
sis/necrosis pathway PARP activity plays
an active role in the transcription of various
proinflammatory genes. Suppression of this
process thus may provide additional car-
dioprotective benefits during and after car-
dioplegia.
The reference made by Bloch and
Mehlhorn to stroke and NAD depletion
does not have any direct relationship to our
current work, but for the record we note
that the vast majority of studies (more than
20 published reports, reviewed in Vira´g
and Szabo´1) demonstrate the marked pro-
tective effect of PARP inhibitors and ge-
netic PARP deficiency in various models of
stroke. In most experimental models of
scular Surgery ● August 2004stroke (similar to myocardial ischemia) a
prenecrotic/necrotic pathway of cell death
(as opposed to apoptosis or PARP cleav-
age) appears to play the dominant role and
can be beneficially affected by PARP inhi-
bition.
Whether inhibition or scavenging of up-
stream effectors of apoptosis or necrosis,
such as reactive oxygen species, would be
more effective by reduction of endogenous
PARP activation in addition to the inhibi-
tion of DNA damage and subsequent cell
death remains to be clarified. We have pre-
clinical experience with the novel porphy-
rinic peroxynitrite decomposition catalyst
FP15,8,9 which shows beneficial effects
during regional ischemia/reperfusion8,9
and after cardioplegic arrest (unpublished
observations).
In conclusion, we maintain that PARP
inhibition is a promising concept for reduc-
ing cell damage during ischemia and reper-
fusion. Even if alternative cardiac surgical
techniques such as beating-heart surgery
minimize ischemia-reperfusion injury,
PARP inhibition may improve postopera-
tive outcome in those cases in which car-
dioplegia is still necessary.
Ga´bor Szabo´, MD, PhDa
Csaba Szabo´, MD, PhD, DScb
Department of Cardiac Surgerya
University of Heidelberg
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